SG Americas Securities LLC Takes $126,000 Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

SG Americas Securities LLC purchased a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the third quarter, Holdings Channel.com reports. The firm purchased 12,358 shares of the company’s stock, valued at approximately $126,000.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of iTeos Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after purchasing an additional 9,660 shares in the last quarter. Dimensional Fund Advisors LP grew its position in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after acquiring an additional 117,159 shares in the last quarter. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the second quarter worth $7,558,000. Acadian Asset Management LLC purchased a new position in iTeos Therapeutics in the first quarter worth $3,337,000. Finally, Clearline Capital LP purchased a new position in iTeos Therapeutics in the second quarter worth $2,328,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ITOS has been the subject of several research reports. Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 target price for the company. Wedbush restated an “outperform” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Monday, September 16th.

iTeos Therapeutics Trading Up 1.4 %

Shares of NASDAQ:ITOS opened at $8.72 on Friday. The company has a market cap of $318.45 million, a price-to-earnings ratio of -2.91 and a beta of 1.36. The company has a 50-day moving average price of $12.64 and a 200-day moving average price of $14.22. iTeos Therapeutics, Inc. has a 12 month low of $8.55 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.86. The firm had revenue of $35.00 million for the quarter, compared to the consensus estimate of $4.20 million. As a group, research analysts forecast that iTeos Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.